Amicus Therapeutics, Inc. (FOLD) Insider Hung Do Sells 50,194 Shares
Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider Hung Do sold 50,194 shares of the company’s stock in a transaction that occurred on Thursday, October 12th. The stock was sold at an average price of $14.25, for a total value of $715,264.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Amicus Therapeutics, Inc. (NASDAQ FOLD) traded up 1.45% during mid-day trading on Monday, reaching $14.74. The company’s stock had a trading volume of 2,070,898 shares. The firm’s 50 day moving average is $14.39 and its 200-day moving average is $10.90. The stock’s market cap is $2.43 billion. Amicus Therapeutics, Inc. has a one year low of $4.41 and a one year high of $16.60.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. The business had revenue of $7.16 million for the quarter, compared to the consensus estimate of $6.96 million. During the same period in the prior year, the firm earned ($0.40) EPS. Equities analysts expect that Amicus Therapeutics, Inc. will post ($1.32) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.dailypolitical.com/2017/10/16/amicus-therapeutics-inc-fold-insider-hung-do-sells-50194-shares.html.
Several brokerages have recently commented on FOLD. Leerink Swann reissued an “outperform” rating and issued a $17.00 price objective (down from $18.00) on shares of Amicus Therapeutics in a research note on Saturday, September 16th. Zacks Investment Research lowered Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. BidaskClub lowered Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 2nd. Cowen and Company reaffirmed a “buy” rating and issued a $16.00 target price (up from $10.00) on shares of Amicus Therapeutics in a report on Tuesday, July 11th. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $17.00 price objective on shares of Amicus Therapeutics in a report on Friday, October 6th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $17.81.
A number of large investors have recently bought and sold shares of FOLD. Russell Investments Group Ltd. lifted its position in Amicus Therapeutics by 1,004.9% during the first quarter. Russell Investments Group Ltd. now owns 121,338 shares of the biopharmaceutical company’s stock valued at $865,000 after acquiring an additional 110,356 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Amicus Therapeutics by 51.7% in the first quarter. Wells Fargo & Company MN now owns 153,473 shares of the biopharmaceutical company’s stock worth $1,094,000 after buying an additional 52,287 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Amicus Therapeutics by 12.5% in the first quarter. Bank of New York Mellon Corp now owns 672,463 shares of the biopharmaceutical company’s stock worth $4,794,000 after buying an additional 74,700 shares during the last quarter. UBS Asset Management Americas Inc. raised its holdings in shares of Amicus Therapeutics by 71.8% in the first quarter. UBS Asset Management Americas Inc. now owns 50,674 shares of the biopharmaceutical company’s stock worth $361,000 after buying an additional 21,174 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Amicus Therapeutics by 3.2% in the first quarter. JPMorgan Chase & Co. now owns 1,465,914 shares of the biopharmaceutical company’s stock worth $10,452,000 after buying an additional 44,828 shares during the last quarter.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.